| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d137f8e7503ba75f6edf7cbdf54e98c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-82 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-04 |
| filingDate |
2012-09-21^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-01-05^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86d859d2bc944308436f86e2c16ee9d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95dd31e2aa4544b3df5ab5e93668a732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53b51b4ece78e934698552f7e2d18af8 |
| publicationDate |
2016-01-05^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9227965-B2 |
| titleOfInvention |
Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV |
| abstract |
Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition of a water-miscible organic solvent to the aqueous solution and, again without removing water, adding cinchonidine to the aqueous-organic solvent solution so as to obtain the cinchonidine salt of the lactone acid. The cinchonidine salt is allowd to crystallize so as to obtain the enantiomerically purified crystalline lactone acid cinchonidine salt (IV). The enantiomerically pure salt is an intermediate in the synthesis of HCV inhibitor compound of formula (I). |
| priorityDate |
2011-09-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |